Active, not recruitingPHASE2, PHASE3NCT06450886
Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
Studying Inclusion body myositis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Abcuro, Inc.
- Intervention
- Ulviprubart (ABC008)(drug)
- Enrollment
- 270 enrolled
- Eligibility
- 40 years · All sexes
- Timeline
- 2024 – 2029
Study locations (21)
- Neuromuscular Research Center, Phoenix, Arizona, United States
- University of California Irvine Medical Center (UCIMC) - Amyotrophic Lateral Sclerosis (ALS) and Neuromuscular Center, Irvine, California, United States
- Keck Hospital of USC, Los Angeles, California, United States
- Yale School of Medicine, New Haven, Connecticut, United States
- Neuromuscular Diagnostic Center - Massachusetts General Hospital, Boston, Massachusetts, United States
- Brigham and Womens Hospital, Boston, Massachusetts, United States
- Hospital for Special Surgery, New York, New York, United States
- Duke Neurological Disorders Clinic, Durham, North Carolina, United States
- University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- Ohio State University Wexner Medical Center, Columbus, Ohio, United States
- Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- UPMC Arthritis and Autoimmunity Center, Falk Clinic, Pittsburgh, Pennsylvania, United States
- Austin Neuromuscular Center, Austin, Texas, United States
- Texas Neurology, Dallas, Texas, United States
- +6 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06450886 on ClinicalTrials.govOther trials for Inclusion body myositis
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT07072676The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.LMU Klinikum
- RECRUITINGPHASE2NCT06536166Ruxolitinib Treatment in Inclusion Body MyositisAssistance Publique - Hôpitaux de Paris
- RECRUITINGEARLY PHASE1NCT06479863Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body MyositisAustin Neuromuscular Center
- ACTIVE NOT RECRUITINGNCT06153108Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over TimeUniversity of Kansas Medical Center
- ACTIVE NOT RECRUITINGPHASE3NCT04789070Phase III Trial of Sirolimus in IBMUniversity of Kansas Medical Center
- ACTIVE NOT RECRUITINGNCT05046821Sporadic Inclusion Body Myositis Natural History StudyUniversity of California, Irvine